SLC39A3 encodes a zinc transporter protein that mediates zinc influx across the plasma membrane into cells from extracellular space. This transporter belongs to the SLC39 family of zinc importers, which show tissue-restricted expression patterns consistent with organ-specific functions 1. SLC39A3 demonstrates significant disease associations across multiple contexts. In cancer, SLC39A3 expression is upregulated in breast cancer tissues compared to normal tissues, and high expression correlates with worse overall survival 2. Similarly, in lung adenocarcinoma, SLC39A3 expression levels are significantly associated with patient prognosis 3. Transcriptome-wide association studies have identified SLC39A3 as protective against bladder cancer risk, with higher expression levels associated with reduced disease susceptibility 4. Beyond cancer, SLC39A3 has been implicated in neuropsychiatric disorders, with associations reported for both bipolar disorder 5 and potential involvement in late-onset Alzheimer's disease through a chromosome 19 genetic pattern 6. The gene's role in metal ion homeostasis may be particularly relevant to brain function, as disrupted zinc transport has been linked to psychosis 7. These findings suggest SLC39A3 serves as both a prognostic biomarker and potential therapeutic target across multiple disease contexts.